CALCIUM, ESTROGEN, AND PROGESTIN IN THE TREATMENT OF OSTEOPOROSIS

Neil A. Breslau
In: Rheumatic Disease Clinics of North America · 1994 · vol. 20(3) , pp. 691–716 · doi:10.1016/s0889-857x(21)00356-2 · PMID:7984785 · W138557223
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-12 ⓘ

This paper investigates the combined effects of calcium, estrogen, and progestin in treating osteoporosis, examining their impact on bone health.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

An adequate calcium intake is important to attain peak bone mass and to oppose that component of age-related bone loss due to insufficient intestinal calcium absorption. Calcium and appropriate vitamin D supplements are particularly important for preventing cortical bone loss and associated hip fractures in the elderly (Type II osteoporosis). Within the initial 5 years following menopause, there is an accelerated loss of trabecular bone from the spine and distal radius (Type I osteoporosis). At that time, estrogen replacement is most effective for preventing the rapid trabecular bone loss that could otherwise result in vertebral or Colles' fractures. During this early period of estrogen deficiency when excessive bone turnover is releasing large amounts of calcium into the circulation, supplemental calcium is ineffective. Progesterone, often given with estrogen to prevent endometrial carcinoma, may itself have a trophic influence on bone.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

References (100)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-07-27T06:55:32.580041+00:00
License: CC0 · commercial use OK